Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.
Cytek Biosciences, Inc. (Nasdaq: CTKB) is a cell analysis solutions company focused on high-parameter flow cytometry using its patented Full Spectrum Profiling™ (FSP®) technology. This news page aggregates coverage of Cytek’s announcements so readers can follow developments related to its instruments, reagents, services and corporate activities.
Company press releases frequently address financial results and outlook, including quarterly revenue performance, recurring revenue trends from service and reagent businesses, and updates on installed instrument base. Cytek also issues news when it provides preliminary revenue expectations or reaffirms full-year guidance, and these items are often accompanied by Form 8-K filings summarizing results of operations.
Another major category of CTKB news involves product and technology updates. Recent communications have highlighted the launch of the Cytek Aurora™ Evo full spectrum flow cytometer, enhancements to small particle detection, and initiatives to expand access to advanced cytometry tools through instrument awards and research grants. The company also reports on the use of its FSP systems in peer-reviewed research and at scientific meetings.
Investors and researchers will also find corporate and recognition news, such as Cytek’s inclusion on TIME’s 2026 list of America’s Growth Leaders, expansion of its European headquarters in Amsterdam, and participation in healthcare and investor conferences hosted by organizations including UBS, Morgan Stanley, Stephens and Piper Sandler. Updates on collaborations with groups like the International Society for Advancement of Cytometry (ISAC) and presence at clinical cytometry conferences such as ESCCA and ICCS are also covered.
By reviewing CTKB news, users can track how Cytek communicates its financial performance, product evolution, geographic expansion and engagement with the scientific and investment communities over time.
Cytek Biosciences (Nasdaq: CTKB), a leading cell analysis solutions company, has announced its participation in several upcoming investor conferences in early 2025. The schedule includes:
- BTIG 12th Annual MedTech Conference in Snowbird, UT (February 11-12, 2025)
- Raymond James 46th Annual Institutional Investors Conference in Orlando, FL (March 3, 2025, at 3:25 PM ET)
- TD Cowen 45th Annual Health Care Conference in Boston, MA (March 5, 2025, at 10:30 AM ET)
- Leerink Partners Global Healthcare Conference in Miami, FL (March 10-12, 2025)
Live and archived webcasts for the Raymond James and TD Cowen conferences will be available on the company's investor relations website at investors.cytekbio.com.
Cytek Biosciences (CTKB) has announced preliminary unaudited revenue results for 2024, expecting full-year revenue between $200-201 million, representing 4% growth over 2023's $193.0 million. The company faced a $1.0 million negative foreign exchange impact.
Fourth quarter revenue is expected to be $57-58 million, showing 11-13% growth compared to Q3 2024, but a 2% decline to flat performance versus Q4 2023. The quarter was impacted by a $1.5 million negative effect from US dollar appreciation and order delays in some markets, although Asia Pacific and Rest of World markets showed strong growth.
The company will report detailed financial results and provide 2025 guidance during its earnings call expected in late February 2025.
Cytek Biosciences (Nasdaq: CTKB), a leading cell analysis solutions company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management will deliver a presentation on Thursday, January 16th at 8:15 a.m. Pacific Time (11:15 a.m. Eastern Time).
Investors and interested parties can access both live and archived versions of the presentation through the 'Investors' section of Cytek's website at investors.cytekbio.com.
Cytek Biosciences (CTKB) has announced a new $50 million stock repurchase program for 2025, succeeding its current program expiring December 31, 2024. The new program will run from January 1 to December 31, 2025, unless modified by the Board of Directors. Repurchases will be conducted in the open market and/or through private negotiations, in compliance with SEC Rule 10b-18. The timing and amount of repurchases will depend on factors including liquidity, cash flow, and market conditions. The company maintains discretion to modify or suspend the program at any time.
Cytek Biosciences (Nasdaq: CTKB) announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York. The company's management will engage in a fireside chat on Tuesday, December 3, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). A live and archived webcast of the presentation will be available to interested parties through the 'Investors' section of Cytek's website at investors.cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB) has been named 'Overall BioTech Company of the Year' in the 2024 BioTech Breakthrough Awards program, which attracted nominations from 14 countries. The company is recognized for its pioneering work in spectral flow cytometry and its Full Spectrum Profiling™ technology. Cytek's platform includes the Aurora™ and Northern Lights™ systems, the Aurora™ CS cell sorter, and Amnis® and Guava® branded products. The company's impact is evidenced by over 2,100 peer-reviewed articles and its commitment to making flow cytometry more accessible for research and clinical applications.
Cytek Biosciences (CTKB) has launched the world's first Enhanced Small Particle (ESP™) Detection Option for its Aurora™ CS cell sorter system. This groundbreaking technology enables detection and sorting of particles as small as 70 nm, including exosomes and extracellular vesicles (EVs). The system builds on Cytek's Full Spectrum Profiling™ technology and allows seamless assay transfer from analyzer to sorter. This advancement is particularly significant for research in drug delivery, cell therapy, disease diagnostics, and vaccine delivery, enabling researchers to analyze materials previously impossible to sort.
Cytek Biosciences (CTKB) reported Q3 2024 financial results with total revenue of $51.5 million, up 7% year-over-year and 10% quarter-over-quarter. The company achieved $143.0 million in year-to-date revenue, 6% above the same period in 2023. Notable developments include the launch of SpectroPanel™ tool and expansion of installed base to 2,821 instruments. Q3 showed a net income of $0.9 million, improving from a $6.5 million loss in Q3 2023. The company maintains its 2024 revenue guidance of $203-210 million, projecting 5-9% growth. Cash position remained strong at $277.8 million, with $12.1 million used for share repurchases during Q3.
Cytek Biosciences (Nasdaq: CTKB) has announced its participation in two major investor conferences in November 2024. The company will present at the Guggenheim Inaugural Healthcare Conference in Boston on November 11 at 11:00 a.m. ET, featuring a fireside chat. Additionally, they will deliver a presentation at the UBS Global Healthcare Conference in Rancho Palos Verdes on November 13 at 4:15 p.m. PT. Both presentations will be accessible via live and archived webcasts on the company's investor relations website.
Cytek Biosciences (Nasdaq: CTKB) has announced it will release its third quarter 2024 financial results after market close on Tuesday, November 5, 2024. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss results, business developments, and outlook. The webcast will be accessible through the Investors section of Cytek's website.
FAQ
What is the current stock price of Cytek Biosciences (CTKB)?
What is the market cap of Cytek Biosciences (CTKB)?
